5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer

M. Lopez, M. Natali, L. Di Lauro, G. Tonini, S. Carpano, P. Vici, E. M S Conti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Forty-eight patients with advanced measurable gastric cancer were treated with the three-drug combination of 5-fluorouracil, epirubicin, and BCNU (FEB). The response rate was 42% in 45 evaluable patients. There were five complete responders (11%). The median duration of response was 13 months, and the median survival of all patients was 9.2 months. Toxicity was generally mild to moderate. No instances of congestive heart failure were recorded. These results indicate that patients with metastatic gastric cancer can be effectively palliated with FEB chemotherapy.

Original languageEnglish
Pages (from-to)204-207
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number3
Publication statusPublished - 1990

Fingerprint

Carmustine
Epirubicin
Fluorouracil
Stomach Neoplasms
Drug Combinations
Heart Failure
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lopez, M., Natali, M., Di Lauro, L., Tonini, G., Carpano, S., Vici, P., & Conti, E. M. S. (1990). 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 13(3), 204-207.

5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. / Lopez, M.; Natali, M.; Di Lauro, L.; Tonini, G.; Carpano, S.; Vici, P.; Conti, E. M S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 3, 1990, p. 204-207.

Research output: Contribution to journalArticle

Lopez, M, Natali, M, Di Lauro, L, Tonini, G, Carpano, S, Vici, P & Conti, EMS 1990, '5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 13, no. 3, pp. 204-207.
Lopez, M. ; Natali, M. ; Di Lauro, L. ; Tonini, G. ; Carpano, S. ; Vici, P. ; Conti, E. M S. / 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 3. pp. 204-207.
@article{b9a20cc5cbe64a608a11b5eb3b6c530d,
title = "5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer",
abstract = "Forty-eight patients with advanced measurable gastric cancer were treated with the three-drug combination of 5-fluorouracil, epirubicin, and BCNU (FEB). The response rate was 42{\%} in 45 evaluable patients. There were five complete responders (11{\%}). The median duration of response was 13 months, and the median survival of all patients was 9.2 months. Toxicity was generally mild to moderate. No instances of congestive heart failure were recorded. These results indicate that patients with metastatic gastric cancer can be effectively palliated with FEB chemotherapy.",
author = "M. Lopez and M. Natali and {Di Lauro}, L. and G. Tonini and S. Carpano and P. Vici and Conti, {E. M S}",
year = "1990",
language = "English",
volume = "13",
pages = "204--207",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer

AU - Lopez, M.

AU - Natali, M.

AU - Di Lauro, L.

AU - Tonini, G.

AU - Carpano, S.

AU - Vici, P.

AU - Conti, E. M S

PY - 1990

Y1 - 1990

N2 - Forty-eight patients with advanced measurable gastric cancer were treated with the three-drug combination of 5-fluorouracil, epirubicin, and BCNU (FEB). The response rate was 42% in 45 evaluable patients. There were five complete responders (11%). The median duration of response was 13 months, and the median survival of all patients was 9.2 months. Toxicity was generally mild to moderate. No instances of congestive heart failure were recorded. These results indicate that patients with metastatic gastric cancer can be effectively palliated with FEB chemotherapy.

AB - Forty-eight patients with advanced measurable gastric cancer were treated with the three-drug combination of 5-fluorouracil, epirubicin, and BCNU (FEB). The response rate was 42% in 45 evaluable patients. There were five complete responders (11%). The median duration of response was 13 months, and the median survival of all patients was 9.2 months. Toxicity was generally mild to moderate. No instances of congestive heart failure were recorded. These results indicate that patients with metastatic gastric cancer can be effectively palliated with FEB chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0025170559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025170559&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 204

EP - 207

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -